The first-of-its-kind Center aims to advance new treatment approaches for patients with RAS mutant cancers.
Shortages led to a 2.7% decrease in use of two common platinum-based chemotherapies: cisplatin and carboplatin.
A conversation with Stacy Loeb, MD Professor of Urology and Population Health at NYU Langone Health and the Manhattan VA.